retatrutide phase 2 nejm 2023 obesity trial jastreboff Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide Phase 3 Results 2026:

have shown that compared with intravenous glucose, the increase of plasma insulin level after oral glucose was greater, and the high level of insulin was maintained for a longer time, which provided a basis for intestinal factors to stimulate insulin secretion (Elrick et al., 1964)

Glucagonlike peptide1: actions and influence on pancreatic hormone function

This is where the marketing often gets ahead of the medicine

Aging rewires metabolism, immunity, and gene regulation across organs, steadily sapping strength, cognition, and resilience

Some are prescribed off-label by medical providers

A Fountain of Youth These drugs appear to be a virtual fountain of youth